Common side effects (most men experience some)
- Water retention in weeks 1-4. Resolves naturally; minor cosmetic effect.
- Acne, oily skin. Most common in men with naturally elevated androgen receptor sensitivity. Improves over time.
- Mild hematocrit elevation (44 → 48-50%). Monitor; phlebotomy or dose reduction if >52%.
- Suppressed fertility. Universal on TRT alone, see fertility on TRT.
- Body and facial hair changes. Variable; depends on genetics.
- Mild emotional changes in first 4 weeks as levels stabilize. Usually positive (mood lift).
Less common, monitorable
- Significant polycythemia. Hematocrit >54% or hemoglobin >18. Manageable with phlebotomy, dose adjustment, hydration.
- Estradiol elevation with mood/water/breast issues. Address with dose tweak before adding aromatase inhibitor, see estradiol on TRT.
- Worsened sleep apnea in men with pre-existing obstructive sleep apnea. CPAP or weight loss usually addresses; rule out before starting.
- Gynecomastia if estradiol rises significantly without correction.
- Increased aggression in some men. Often related to dose or estradiol pattern; usually resolved by protocol adjustment.
Rare
- Significant lipid changes. Most TRT improves lipids; a minority see HDL drop modestly.
- Severe mood disturbance. Investigate underlying issues (estradiol crash, hematocrit, sleep apnea) before discontinuing.
- Injection site reactions. Usually technique issues; rotate sites.
Concerns now resolved
- Cardiovascular events. TRAVERSE 2023/2024, n=5,200 men with pre-existing CVD, 33-month follow-up, showed no increase in MACE on TRT vs placebo.
- Prostate cancer. Multiple meta-analyses now show no causal link between physiologic TRT and prostate cancer initiation.
- Heart attack risk. The 2014 observational signal that started the panic has not replicated in any RCT.
How to minimize each
| Side effect | Mitigation |
|---|---|
| Water retention | Wait 4 weeks; reduce sodium temporarily |
| Acne | Skincare; usually self-resolves |
| Polycythemia | Hydration, blood donation, dose adjustment |
| Fertility loss | HCG concurrent; or sperm bank pre-TRT |
| Estradiol issues | Sensitive E2 testing; dose adjustment first; AI only if confirmed |
| Sleep apnea | Rule out at baseline; CPAP if present |
| Gynecomastia | Manage estradiol proactively |
The principle: Most TRT side effects are managed by good protocol design and lab monitoring. The "I had a bad TRT experience" stories almost always trace back to inadequate monitoring or unmonitored gray-market products.
Bottom line
TRT has real side effects but a favorable risk-benefit profile when properly managed. The major historical concerns (cardiovascular, prostate cancer) have been resolved by modern data. Quarterly lab monitoring in the first year catches the manageable issues early. The risks are small and known; the benefits, when treating documented hypogonadism, are substantial.
5-10%
of TRT patients see hematocrit need active management
No ↑
cardiovascular risk in TRAVERSE
Quarterly
labs in year 1 catch most issues early